Daiichi Sankyo Archives -

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

News/ News/ Oncology

ASCO22: Enhertu aces key HER2-low test in breast cancer

Phil Taylor ASCO 2022, AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, Oncology 0 Comment

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast

ASCO22: Enhertu aces key HER2-low test in breast cancer

https://pharmaphorum.com/news/asco22-enhertu-aces-key-her2-low-test-in-breast-cancer/

News/ News/ News/ Oncology/ Sales and Marketing

SEC accuses former AstraZeneca exec of insider trading

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, insider trading, Kadmon, litigation, Sanofi, SEC 0 Comment

The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection

SEC accuses former AstraZeneca exec of insider trading

https://pharmaphorum.com/news/sec-accuses-former-astrazeneca-exec-of-insider-trading/

Digital/ News/ News

Takeda, Daiichi-backed wearable study planned in Japan

Phil Taylor Daiichi Sankyo, digital, digital health, Takeda, wearable 0 Comment

A study that will look at the feasibility of tracking people’s lifestyle habits for an extended period using

Takeda, Daiichi-backed wearable study planned in Japan

https://pharmaphorum.com/news/takeda-daiichi-backed-wearable-study-planned-in-japan/

Market Access/ News/ News/ News/ Oncology

Enhertu gets breakthrough tag in HER2-low breast cancer

Phil Taylor antibody-drug conjugate, AstraZeneca, breakthrough Therapy, breast cancer, Daiichi Sankyo, Enhertu, her2, Oncology 0 Comment

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing

Enhertu gets breakthrough tag in HER2-low breast cancer

https://pharmaphorum.com/news/enhertu-gets-breakthrough-tag-in-her2-low-breast-cancer/

Market Access/ News/ News/ News/ Oncology

FDA starts speedy review of Enhertu in lung cancer

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, her2, Non-small cell lung cancer 0 Comment

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if

FDA starts speedy review of Enhertu in lung cancer

https://pharmaphorum.com/news/fda-starts-speedy-review-of-enhertu-in-lung-cancer/

News/ News/ Sales and Marketing

Seagen wins Enhertu patent dispute with Daiichi Sankyo

Phil Taylor antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, Enhertu, patent litigation, Seagen 0 Comment

A US jury has decided that Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu infringes a patent held

Seagen wins Enhertu patent dispute with Daiichi Sankyo

https://pharmaphorum.com/news/seagen-wins-enhertu-patent-dispute-with-daiichi-sankyo/

News/ News/ Oncology

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, her2 0 Comment

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

https://pharmaphorum.com/news/big-day-for-az-daiichi-as-enhertu-aces-her2-low-breast-cancer-trial/

News/ News/ R&D

Daiichi makes play for share of Japan’s COVID booster market

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, Daiichi Sankyo, Japan, Omicron 0 Comment

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new

Daiichi makes play for share of Japan’s COVID booster market

https://pharmaphorum.com/news/daiichi-makes-play-for-share-of-japans-covid-booster-market/

Trending

Daiichi Sankyo

Login